Viewing Study NCT04567420


Ignite Creation Date: 2025-12-25 @ 4:24 AM
Ignite Modification Date: 2025-12-26 @ 3:27 AM
Study NCT ID: NCT04567420
Status: RECRUITING
Last Update Posted: 2025-10-16
First Post: 2020-09-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Sponsor: Criterium, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module